Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer – a nationwide, retrospective study
DOI:
https://doi.org/10.2340/1651-226X.2024.38886Keywords:
Breast Cancer, Advanced Breast Cancer, HER2-normal, Capecitabine, Chemotherapy, Overall Survival, Progression Free SurvivalAbstract
Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Human Epidermal Growth Factor Receptor (HER2)-normal advanced breast cancer treated with capecitabine monotherapy as first-line treatment.
Material and Methods: The study utilized the Danish Breast Cancer Group (DBCG) database and was conducted retrospectively across all Danish oncology departments. Inclusion criteria were female patients, with HER2-normal advanced breast cancer treated with capecitabine monotherapy as the first-line treatment from 2010 to 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS).
Results: A total of 494 patients were included. Median OS was 16.4 months (95% confidence interval [CI]: 14.5–18.0), and median PFS was 6.0 months (95% CI: 5.3–6.7). Patients with estrogen receptor (ER)-positive disease had significantly longer OS (median: 22.8 vs. 10.5 months, p < 0.001) and PFS (median: 7.4 vs. 4.9 months, p = 0.003), when compared to ER-negative patients. Stratifying by age, patients under 45 years displayed a median PFS of 4.1 months, while those aged 45–70 years and over 70 years had median PFS of 5.7 and 7.2 months, respectively (p = 0.01).
Interpretation: In this nationwide study, the efficacy of capecitabine as a first-line treatment for HER2-normal advanced breast cancer is consistent with other, mainly retrospective, studies. However, when assessed against contemporary and newer treatments, its effectiveness appears inferior to alternative chemotherapies or targeted therapies.
Downloads
References
Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016 Jun;55 Suppl 2:24–35.
https://doi.org/10.3109/0284186X.2015.1128119 DOI: https://doi.org/10.3109/0284186X.2015.1128119
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017 Nov;377(19):1836–46.
https://doi.org/10.1056/NEJMoa1701830 DOI: https://doi.org/10.1056/NEJMoa1701830
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020. Volume 138, Pages S4-S4.
https://doi.org/10.1016/S0959-8049(20)30540-2 DOI: https://doi.org/10.1016/S0959-8049(20)30540-2
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021 Dec;39(35):3959–77.
https://doi.org/10.1200/JCO.21.01392 DOI: https://doi.org/10.1200/JCO.21.01392
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.
https://doi.org/10.1016/j.annonc.2020.09.010 DOI: https://doi.org/10.1016/j.annonc.2020.09.010
European Medicines Association. Mabthera, Scientific Discussion. 2005 [cited 2023 Oct 6]. p. 1–54. Xeloda EPAR – scientific discussion. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf
European Medicines Association. Xeloda EPAR – procedural steps taken before authorisation [Internet]. 2005 [cited 2023 Oct 6]. p. 1. Available from: https://www.ema.europa.eu/en/documents/procedural-steps/xeloda-epar-procedural-steps-taken-authorisation_en.pdf
O’Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist. 2012;17(4):476–84.
https://doi.org/10.1634/theoncologist.2011-0281 DOI: https://doi.org/10.1634/theoncologist.2011-0281
Kaufmann M, Maass N, Costa SD, Schneeweiss A, Loibl S, Sütterlin MW, et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur J Cancer. 2010 Dec;46(18):3184–91.
https://doi.org/10.1016/j.ejca.2010.07.009 DOI: https://doi.org/10.1016/j.ejca.2010.07.009
Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017 Jan;161(1):63–72.
https://doi.org/10.1007/s10549-016-4033-3 DOI: https://doi.org/10.1007/s10549-016-4033-3
Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001 Sep;12(9):1247–54.
https://doi.org/10.1023/A:1012281104865 DOI: https://doi.org/10.1023/A:1012281104865
Oostendorp LJM, Stalmeier PFM, Donders ART, van der Graaf WTA, Ottevanger PB. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 2011 Oct;12(11): 1053–61.
https://doi.org/10.1016/S1470-2045(11)70045-6 DOI: https://doi.org/10.1016/S1470-2045(11)70045-6
Alsaloumi L, Shawagfeh S, Abdi A, Basgut B. Efficacy and safety of Capecitabine alone or in combination in advanced metastatic breast cancer patients previously treated with Anthracycline and Taxane: a systematic review and meta-analysis. Oncol Res Treat. 2020;43: 694–702.
https://doi.org/10.1159/000510356 DOI: https://doi.org/10.1159/000510356
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J Clin Oncol. 2021 Dec;39(35):3938–58. DOI: https://doi.org/10.1200/JCO.21.01374
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.
https://doi.org/10.1016/j.annonc.2021.09.019 DOI: https://doi.org/10.1016/j.annonc.2021.09.019
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep;34(25):3069–103.
https://doi.org/10.1200/JCO.2016.67.1487 DOI: https://doi.org/10.1200/JCO.2016.67.1487
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2021 Apr;32(4):488–99.
https://doi.org/10.1016/j.annonc.2020.12.013 DOI: https://doi.org/10.1016/j.annonc.2020.12.013
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb;33(6):594–601.
https://doi.org/10.1200/JCO.2013.52.4892 DOI: https://doi.org/10.1200/JCO.2013.52.4892
Ejlertsen B, Offersen BV, Overgaard J, Christiansen P, Jensen MB, Kroman N, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018 Jan;57(1):3–12.
https://doi.org/10.1080/0284186X.2017.1408962 DOI: https://doi.org/10.1080/0284186X.2017.1408962
Jensen MB, Laenkholm AV, Offersen B V, Christiansen P, Kroman N, Mouridsen HT, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018 Jan;57(1):13–8.
https://doi.org/10.1080/0284186X.2017.1404638 DOI: https://doi.org/10.1080/0284186X.2017.1404638
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47.
https://doi.org/10.1016/j.ejca.2008.10.026 DOI: https://doi.org/10.1016/j.ejca.2008.10.026
Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012 Dec;136(3):777–88. DOI: https://doi.org/10.1007/s10549-012-2288-x
Thijssen S, Wildiers H, Punie K, Beuselinck B, Clement P, Remmerie C, et al. Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. J Cancer Res Clin Oncol. 2021 Apr;147(4):1041–8.
https://doi.org/10.1007/s00432-020-03487-1 DOI: https://doi.org/10.1007/s00432-020-03487-1
Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015;101(4):418–23.
https://doi.org/10.5301/tj.5000332 DOI: https://doi.org/10.5301/tj.5000332
Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May;5(5):CD011220.
https://doi.org/10.1002/14651858.CD011220.pub2 DOI: https://doi.org/10.1002/14651858.CD011220.pub2
Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019 Dec;20(12):1750–9.
Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018 Oct;4(10):1367–74.
https://doi.org/10.1001/jamaoncol.2018.2262 DOI: https://doi.org/10.1001/jamaoncol.2018.2262
Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019 Oct;20(10):1360–9.
https://doi.org/10.1016/S1470-2045(19)30420-6 DOI: https://doi.org/10.1016/S1470-2045(19)30420-6
Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016 Feb;27(2):256–62.
https://doi.org/10.1093/annonc/mdv544 DOI: https://doi.org/10.1093/annonc/mdv544
Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast. 2017 Feb;31:114–20.
https://doi.org/10.1016/j.breast.2016.10.021 DOI: https://doi.org/10.1016/j.breast.2016.10.021
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016 Nov;375(20):1925–36. DOI: https://doi.org/10.1056/NEJMoa1607303
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov;35(32):3638–46.
https://doi.org/10.1200/JCO.2017.75.6155 DOI: https://doi.org/10.1200/JCO.2017.75.6155
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with Ribociclib plus Letrozole in advanced breast cancer. N Engl J Med. 2022 Mar;386(10):942–50. DOI: https://doi.org/10.1056/NEJMoa2114663
Garly R, Berg T, Jensen MB, Knoop A, Volmer L, Glavicic V, et al. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark. Acta Oncol. 2023 Mar;62(3):290–7.
https://doi.org/10.1080/0284186X.2023.2194030 DOI: https://doi.org/10.1080/0284186X.2023.2194030
DMCG. Systemisk behandling af brystkræft III – palliativ og systemisk behandling af metastaserende brystkræft (MBC), VERSION 1.3 [Internet]. 2021 [cited 2024 Apr 5]. Available from: https://www.dmcg.dk/Kliniske-retningslinjer/kliniske-retningslinjer-opdelt-paa-dmcg/brystcancer/systemisk-behandling-af-brystkraft-iii--palliativ-og-systemisk-behandling-af-metastaserende-brystkraft-mbc/
Behrouzi R, Armstrong AC, Howell SJ. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis. Breast Cancer Res Treat. 2023 Nov;202(1):83–95.
https://doi.org/10.1007/s10549-023-07035-6 DOI: https://doi.org/10.1007/s10549-023-07035-6
Lu YS, Mahidin EIBM, Azim H, ERALP Y, Yap YS, Im SA, et al. Abstract GS1-10: primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Cancer Res. 2023 Mar 1;83(5_Supplement):GS1-10-GS1-10.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-10 DOI: https://doi.org/10.1158/1538-7445.SABCS22-GS1-10
Celik A, Berg T, Jensen MB, Jakobsen E, Nielsen HM, Kümler I, et al. Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer. Breast Cancer (Auckl). 2023;17:11782234231203292.
https://doi.org/10.1177/11782234231203292 DOI: https://doi.org/10.1177/11782234231203292
Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25–36.
https://doi.org/10.4137/BCBCR.S32783 DOI: https://doi.org/10.4137/BCBCR.S32783
Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 2019 Dec 16;21(1):143.
https://doi.org/10.1186/s13058-019-1210-4 DOI: https://doi.org/10.1186/s13058-019-1210-4
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022 Jul;387(3):217–26.
https://doi.org/10.1056/NEJMoa2202809 DOI: https://doi.org/10.1056/NEJMoa2202809
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59.
https://doi.org/10.1016/S1470-2045(19)30689-8 DOI: https://doi.org/10.1016/S1470-2045(19)30689-8
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021 Aug;32(8):994–1004.
Christensen T, Berg T, Nielsen LB, Andersson M, Jensen MB, Knoop A. Dual HER2 blockade in the first-line treatment of metastatic breast cancer – a retrospective population-based observational study in Danish patients. Breast. 2020;51:34–9.
https://doi.org/10.1016/j.breast.2020.03.002 DOI: https://doi.org/10.1016/j.breast.2020.03.002
Prat A, Solovieff N, André F, O’Shaughnessy J, Cameron DA, Janni W, et al. Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with Ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7. Clin Cancer Res. 2024 Feb;30(4):793–802.
https://doi.org/10.1158/1078-0432.CCR-23-0561 DOI: https://doi.org/10.1158/1078-0432.CCR-23-0561
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020 Dec;396(10265):1817–28.
Bonneterre J, Mercier M. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group. Cancer Treat Rev. 1993 Apr;19 Suppl B:21–30.
https://doi.org/10.1016/0305-7372(93)90004-B DOI: https://doi.org/10.1016/0305-7372(93)90004-B
Park IH, Lee KS, Ro J. Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2015 Feb;15(1):e55–62.
https://doi.org/10.1016/j.clbc.2014.09.001 DOI: https://doi.org/10.1016/j.clbc.2014.09.001
Azim HAJ, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014 Aug;16(4):427.
https://doi.org/10.1186/s13058-014-0427-5 DOI: https://doi.org/10.1186/s13058-014-0427-5
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013 Jun;5 Suppl 1(Suppl 1):S2–8.
Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Pediatr Blood Cancer. 2018 Dec;65(12):e27397.
https://doi.org/10.1002/pbc.27397 DOI: https://doi.org/10.1002/pbc.27397
Fredholm H, Magnusson K, Lindström LS, Garmo H, Fält SE, Lindman H, et al. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat. 2016 Nov;160(1):131–43.
https://doi.org/10.1007/s10549-016-3983-9 DOI: https://doi.org/10.1007/s10549-016-3983-9
Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, et al. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016 Nov;160(1):163–72.
https://doi.org/10.1007/s10549-016-3984-8 DOI: https://doi.org/10.1007/s10549-016-3984-8
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Alan Celik, Tobias Berg, Magnus Gibson, Maj-Britt Jensen, Iben Kümler, Saskia Eßer-Naumann, Erik H. Jakobsen, Ann Knoop, Dorte Nielsen
This work is licensed under a Creative Commons Attribution 4.0 International License.
